Company intelligence / Profile preview

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd.

Ownership: Private
Development stage: Commercial

Overview

The company has successfully commercialized recombinant humanized collagen products, including the world's first Recombinant Humanized Type III Collagen approved by NMPA. They also have an Anti-HPV protein product on the market.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Recombinant proteinsCollagen-based productsProtein-based
Industry: Biotech

Drug pipeline

8 assets

recombinant human type III collagen

7 more assets in the full pipeline.

Request access →

Partnerships

L'Oréal (supplier of recombinant collagen ingredients)

Beyond the preview

Go deeper on Shanxi Jinbo Bio-Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanxi Jinbo Bio-Pharmaceutical Co., Ltd..

Explore the full profile